ReviewJournal of anxiety disorders2012
Pharmacological treatment of anxiety disorders: current treatments and future directions.
Review in Journal of anxiety disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 186 citations in OpenAlex.
- Cognitive rehabilitation in anxiety disorders: a systematic review and meta-analysis of randomized controlled trials.Scientific reports · 2025Pooled it
- Effect of Forest Therapy on Depression and Anxiety: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021Pooled it
- Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.Depression and anxiety · 2019Pooled it
- The Effect of Tai Chi Chuan on Negative Emotions in Non-Clinical Populations: A Meta-Analysis and Systematic Review.International journal of environmental research and public health · 2019Pooled it
- Modulation of naturalistic maladaptive memories using behavioural and pharmacological reconsolidation-interfering strategies: a systematic review and meta-analysis of clinical and 'sub-clinical' studies.Psychopharmacology · 2018Pooled it
- Neuroimaging Insights: Kava's (Nutrients · 2023Trial
- First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.British journal of clinical pharmacology · 2020Trial
- Trial
- Neurobiological Mechanisms of Vitamin D in Anxiety: Evidence from Rodent Models and Bioinformatics-Based Target Identification.Nutrients · 2026Review
- Sensory hyperacusis as a predictor of anxiety in adolescence.Journal of child psychology and psychiatry, and allied disciplines · 2026Article
- Mitochondrial dysfunction in perimenopausal mood disorders: From hormonal shifts to neuroenergetic failure (Review).International journal of molecular medicine · 2025Review
- The Role of Neuroinflammation in the Comorbidity of Psychiatric Disorders and Internal Diseases.Healthcare (Basel, Switzerland) · 2025Review
- Article
- Unraveling the Liver-Brain Axis: Resveratrol's Modulation of Key Enzymes in Stress-Related Anxiety.Biomedicines · 2024Article
- Alcohol Consumption Is a Coping Mechanism for Male Patients with Severe Anxiety Disorders Treated with Antidepressants Monotherapy.Journal of clinical medicine · 2024Article
- Loneliness in adolescence and prescription of psychotropic drugs in adulthood: 23-year longitudinal population-based and registry study.BJPsych open · 2024Article
- β-Carboline (FG-7142) modulates fear but not anxiety-like behaviour in zebrafish.Scientific reports · 2024Article
- Emotional Stress and Immune Response in Surgery: A Psychoneuroimmunological Perspective.Cureus · 2023Review
- Decrease in the Ratio proBDNF/BDNF in the Urine of Aging Female Patients with OAB.Metabolites · 2023Article
- Effects of a Gamified, Behavior Change Technique-Based Mobile App on Increasing Physical Activity and Reducing Anxiety in Adults With Autism Spectrum Disorder: Feasibility Randomized Controlled Trial.JMIR formative research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Modern pharmacological treatments for anxiety disorders are safer and more tolerable than they were 30 years ago. Unfortunately, treatment efficacy and duration have not improved in most cases despite a greater understanding of the pathophysiology of anxiety. Moreover, innovative treatments have not reached the market despite billions of research dollars invested in drug development. In reviewing the literature on current treatments, we argue that evidence-based practice would benefit from better research on the causes of incomplete treatment response as well as the comparative efficacy of drug combinations and sequencing. We also survey two broad approaches to the development of innovative anxiety treatments:the continued development of drugs based on specific neuroreceptors and the pharmacological manipulation of fear-related memory. We highlight directions for future research, as neither of these approaches is ready for routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.